CSCC Case Raises Questions About Implications of Early Response to Cemiplimab - AJMC.com Managed Markets Network

A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.

Although most patients with cutaneous squamous cell carcinoma (CSCC) can be surgically cured, a new case report highlights the challenges of finding the right therapy for patients with locally advanc… [+4335 chars]

full article...